Edgen Stock·Sep 08 2025, 18:45戻る
戻る
Black Diamond Therapeutics Stock Advances on Silevertinib Progress and Strategic Restructuring
Edgen Stock·Sep 08 2025, 18:45
[1] BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth? (https://finance.yahoo.com/news/bdtx-stock-sur ...)[2] Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (https://vertexaisearch.cloud.google.com/groun ...)[3] Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy (https://www.globenewswire.com/news-release/20 ...)